Messchendorp AL, Meijer E, Visser FW, et al. - Among participants of a study evaluating the therapeutic effectiveness of lanreotide in autosomal dominant polycystic kidney disease (ADPKD), researchers assessed tubular damage and inflammation markers as predictors of kidney function decline. They used 24-h urine samples of patients to measure albumin, immunoglobulin G, kidney injury molecule 1, β2 microglobulin (β2MG), heart-type fatty acid-binding protein, neutrophil gelatinase-associated lipocalin, and monocyte chemotactic protein-1 ­(MCP-1), at baseline. They used mixed-model analysis, considering 13 estimated glomerular filtration rates (eGFRs) (chronic kidney disease EPIdemiology) per patient, to compute individual alteration in eGFR during follow-up. They found that ADPKD patients with rapidly progressive disease could be selected via measurement of urinary β2MG and MCP-1 excretion, which displayed a predictive value comparable to or even higher than that of total kidney volume or PKD mutation. Hence, the potential promising value of easy and inexpensive to measure urinary markers was suggested for predicting prognosis in ADPKD.